iPierian to Present Data from Induced Pluripotent Stem Cell Program at ISSCR 8th Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- iPierian,
Inc., the leading biopharmaceutical company focused on creating new
therapeutics using patient-derived induced pluripotent stem cells
(iPSCs), today announced that it will present data from its iPSC
research programs at the International Society for Stem Cell
Research (ISSCR) 8th Annual Meeting, June 16-19, 2010, in San
Francisco, CA.
Data presented in a poster entitled, Discovery of disease gene
expression signature in cells derived from Spinal Muscular Atrophy
(SMA) patients, demonstrate that reprogrammed iPSC lines derived
from SMA patients retain a "memory" of the gene expression profile
of their parental cells. The relatively low variability of iPSC
lines derived from individual patients also suggests that a single
iPSC line is sufficient to represent a specific patient in disease
modeling experiments.
"This study demonstrates that an epigenetic profile of a patient
is retained in reprogrammed cells, which enables the study of
patient-specific disease in an in-vitro environment," said Dr.
Michael Venuti, president and chief scientific officer of iPierian.
"iPSCs offer the potential to study certain conditions in
disease-specific human model systems for the first time, and we
believe our iPS cell technology will ultimately lead to more
effective, targeted therapies for patients worldwide."
The schedule of presentations from iPierian's iPSC program is as follows: Date/Time: Thursday June 17, 2010: 5:30 - 7:30 p.m. PDT Poster Session Title: Discovery of disease gene expression signature in cells derived from Spinal Muscular Atrophy (SMA) patients Location: First floor; Exhibit Hall Date/Time: Thursday June 17, 2010: 5:30 - 7:30 p.m. PDT Poster Session Title: Human induced pluripotent stem cells from peripheral blood of healthy donors Location: First floor; Exhibit Hall Date/Time: Friday, June 18, 2010: 5:30 - 7:30 p.m. PDT Poster Session Title: The role of small molecule inhibitors of p53 in cellular reprogramming Location: First floor; Exhibit Hall Date/Time: Friday, June 18, 2010: 5:30 - 7:30 p.m. PDT Poster Session Title: Identification of small molecules in inducing pluripotency of human fibroblasts through chemical genomics Location: First floor; Exhibit Hall About iPierian
iPierian is the leading biopharmaceutical company focused on the
industrialization of induced pluripotent stem cell (iPSC)
technology, using cellular reprogramming and directed
differentiation of patient cells for the discovery and development
of new therapeutics. iPierian's approach places the patient at the
forefront of the drug discovery process in order to reduce drug
development time and increase the probability of success for drug
candidates by using precise human disease models to develop
proprietary small molecule or biologic therapeutics. The initial
proprietary therapeutic focus of the company is neurodegeneration,
particularly spinal muscular atrophy (SMA), amyotrophic lateral
sclerosis (ALS) and Parkinson's disease, in addition to a broad
therapeutic area program intended for partnering in metabolic
disease.
The company's Scientific Advisory Board (SAB) is comprised of
leading researchers and authorities in the stem cell field,
including individual investigators from the Harvard Stem Cell
Institute, The Gladstone Institute and The University of
California, San Francisco. Our scientific founders are Deepak
Srivastava, M.D., (Gladstone Institute/UCSF), George Q. Daley,
M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D.
(Harvard Stem Cell Institute).
iPierian is located in South San Francisco, California. For more
information, please visit www.ipierian.com.
Source: iPierian, Inc.
CONTACT: Julie McDonnell of iPierian, +1-650-872-4714,
julie.mcdonnell@ipierian.com;
or Danielle Bertrand of WCG, +1-415-946-1056,
dbertrand@wcgworld.com, for
iPierian, Inc.
Web Site: http://www.ipierian.com/
Posted: June 2010
